John E Kemnitzer, Iii

Title: John E. Kemnitzer III: Polymer Chemistry and Pharmaceutical Innovation.

Introduction

John E. Kemnitzer III is an inventor associated with Plainsboro, New Jersey. His patent work spans polymer chemistry and pharmaceutical compositions, including approaches to delivering antifibrotic agents. He is credited with 3 patents.

Latest Patents

One of Kemnitzer’s patents, “Polymer Compositions Comprising Antifibrotic Agents, and Methods of Treatment, Pharmaceutical Compositions, and Methods of Preparation Therefor,” describes a method for delivering antifibrotic agents to address pulmonary hypertension and other diseases involving defects in collagen metabolism. The disclosed approach uses a liposome-encapsulated copolymer conjugate, preferably incorporating a proline analog such as cis-4-hydroxy-L-proline. The patent describes forming a dipeptide with L-lysine before copolymerization, enabling high agent loading and controlled delivery intended to inhibit collagen accumulation while reducing the amount of drug required.

Another patent, “Biphasic Polymerization Process,” concerns improvements to polymerization involving aqueous and water-immiscible organic phases. It describes controlling the aqueous solution’s pH and the addition rates of an acid-forming co-monomer and an acid scavenger to maintain conditions favorable to polymer formation. The process also describes using catalyst ratios to help achieve a predetermined polymer molecular weight.

Career Highlights

Kemnitzer’s listed organizational affiliations include Integra LifeSciences Corporation and Rutgers, The State University of New Jersey. His patent portfolio reflects work at the intersection of polymer processes and biomedical applications.

Collaborations

Kemnitzer’s listed coworkers include Joachim B. Kohn and George L. Brode. Their names appear among the collaborators associated with his patent-related work.

Conclusion

John E. Kemnitzer III’s patents address both the manufacture of polymers and their potential use in therapeutic delivery, highlighting the connection between materials science and pharmaceutical innovation.